Showing 6081-6090 of 10817 results for "".
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog
- FDA Grants 510(k) Clearance to Chemence Medical’s Exofin Fusion Redesignhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-chemence-medicals-exofin-fusion-redesign/2460736/The U.S. Federal Drug Administration gave its nod to Chemence Medical’s redesigned exofin fusion skin closure system. Exofin fusion combines a self-adhering flexible mesh strip and a fast-curing 2-octyl cyanoacrylate topical adhesive to close and seal incisions while forming an im
- New Research Highlights Global Challenge of Leprosyhttps://practicaldermatology.com/news/new-research-highlights-global-challenge-of-leprosy/2460706/The global problem of leprosy may be bigger than recognized, new research suggests. In fact, 40 million individuals around the world require preventive treatment in order to reduce the incidence of leprosy or Hansen’s Disease by 90% in 22 years. The new research by
- Project IMPACT from VisualDX Aims to Reduce Disparities in Medicinehttps://practicaldermatology.com/news/project-impact-from-visualdx-aims-reduce-disparities-in-medicine/2460704/VisualDX is launching Project IMPACT (Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine and highlight ways to bridge gaps of knowledge and improve healthcare outcomes for patients of color. Inaugural members include thought leaders
- FDA Grants Priority Review of NDA for Incyte’s Ruxolitinib Cream for ADhttps://practicaldermatology.com/news/fda-grants-priority-review-of-nda-for-incytes-ruxolitinib-cream-for-ad/2460702/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of Incyte’s ruxolitinib cream for atopic dermatitis (AD) for priority review. The Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2021. Ruxolitinib cream is
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- NRS Awards 2020 Research Grantshttps://practicaldermatology.com/news/nrs-awards-2020-research-grants/2460622/Expect to learn more about the genome of the Demodex mite, the microbiome’s role in rosacea, and the skin and eyelid lipid content of individuals with rosacea.The National Rosacea Society has awarded funding for studies—two new, plus continuing support for one ongoing study—into
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- Practical Dermatology® magazine, Modern Aesthetics® magazine Recognized For Excellence by Folio: Magazinehttps://practicaldermatology.com/news/practical-dermatology-magazine-modern-aesthetics-magazine-recognized-for-excellence-by-folio-magazine/2460546/Bryn Mawr Communications III, LLC is pleased to announce that Practical Dermatology® magazine and sister publication Modern Aesthetics® magazine took home two Honorable Mentions from Folio: Magazine’s 2020 Eddie & Ozzie Awards, including a nod for Editorial Tea
- Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://practicaldermatology.com/news/dr-doris-day-joins-nufabrxs-ad-board/2460523/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredients into fabrics to